Referencer - Behandlingsvejledning

1. Sung CY, Chu NS. Epileptic seizures in elderly people: aetiology and seizure type. AgeAgeing. 1990;19(1):25-30.
2. Sen A, Jette N, Husain M, Sander JW.Epilepsy in older people. Lancet.2020;395(10225):735-48.
3. Bruun E, Kalviainen R, Keranen T. Outcome of initial antiepileptic drug treatment inelderly patients with newly diagnosed epilepsy. Epilepsy Res. 2016;127:60-5.
4. Alsfouk BAA, Hakeem H, Chen Z,Walters M, Brodie MJ, Kwan P. Characteristics andtreatment outcomes of newly diagnosed epilepsy in older people: A 30-year longitudinal cohortstudy. Epilepsia. 2020;61(12):2720-8.
5. Hussain SA, Haut SR, Lipton RB, Derby C, Markowitz SY, Shinnar S. Incidence ofepilepsy in a racially diverse, community-dwelling, elderly cohort: results from the Einstein agingstudy. Epilepsy Res. 2006;71(2-3):195-205.
6. Hernandez-Ronquillo L, Adams S, Ballendine S, Tellez-Zenteno JF. Epilepsy in anelderly population: Classification, etiology and drug resistance. Epilepsy Res. 2018;140:90-4.
7. Lezaic N, Roussy J, Masson H, Jette N, Keezer MR. Epilepsy in the elderly: Uniquechallenges in an increasingly prevalent population.Epilepsy Behav.2020;102:106724.
8. Glauser T, Ben-Menachem E, Bourgeois B, Cnaan A, Guerreiro C, Kalviainen R, et al.Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initialmonotherapy for epileptic seizures and syndromes. Epilepsia. 2013;54(3):551-63.
9. Lattanzi S, Trinka E, Del Giovane C, Nardone R, Silvestrini M, Brigo F. Antiepilepticdrug monotherapy for epilepsy in the elderly: A systematic review and network meta-analysis.Epilepsia. 2019;60(11):2245-54.
10. Werhahn KJ, Trinka E, Dobesberger J, Unterberger I,Baum P, Deckert-Schmitz M, etal.A randomized, double-blind comparison of antiepileptic drug treatment in the elderly withnew-onset focal epilepsy. Epilepsia. 2015;56(3):450-9.
11. Gillam L, Weedon K. Medical research and involuntary mental health patients:implications of proposed changes to legislation in Victoria. Monash Bioeth Rev. 2005;24(4):45-9.
12. Steinhoff BJ, Eckhardt K, Doty P, De Backer M, Brunnert M, Schulze-Bonhage A. Along-term noninterventional safety study of adjunctive lacosamide therapy in patients withepilepsy and uncontrolled partial-onset seizures. Epilepsy Behav. 2016;58:35-43.
13. Bainbridge J, De Backer M, Eckhardt K, Tennigkeit F, Bongardt S, Sen D, et al. Safetyand tolerability of lacosamide monotherapy in the elderly: A subgroup analysis from lacosamidetrials in diabetic neuropathic pain. Epilepsia Open. 2017;2(4):415-23.
14. Zaccara G, Lattanzi S. Comorbidity between epilepsy and cardiac arrhythmias:Implication for treatment. Epilepsy Behav. 2019;97:304-12.
15. Janszky I,Hallqvist J, Tomson T, Ahlbom A, Mukamal KJ, Ahnve S. Increased risk andworse prognosis of myocardial infarction in patients with prior hospitalization for epilepsy--theStockholm Heart Epidemiology Program. Brain. 2009;132(Pt 10):2798-804.
16. Petty SJ,Wilding H, Wark JD. Osteoporosis Associated with Epilepsy and the Use ofAnti-Epileptics-a Review. Curr Osteoporos Rep. 2016;14(2):54-65.
17. Tang BM, Eslick GD, Nowson C, Smith C, Bensoussan A. Use of calcium or calcium incombination with vitamin D supplementation to prevent fractures and bone loss in people aged 50years and older: a meta-analysis. Lancet. 2007;370(9588):657-66.
18. Zhao JG, Zeng XT, Wang J, Liu L. Association Between Calcium or Vitamin DSupplementation and Fracture Incidence in Community-Dwelling Older Adults: A SystematicReview and Meta-analysis. JAMA. 2017;318(24):2466-82.
19. Pack A. Bone health in people with epilepsy: is it impaired and what are the riskfactors?Seizure. 2008;17(2):181-6.
20. French JA, Perucca E, Sander JW, Bergfeldt L, Baulac M, Auerbach DS, et al.FDAsafety warning on the cardiac effects of lamotrigine: An advisory from the Ad Hoc ILAE/AES TaskForce. Epilepsia Open. 2021;6(1):45-8.
21. Pack AM, Morrell MJ. Epilepsy andbone health in adults. Epilepsy Behav. 2004;5Suppl 2:S24-9.
22. Vestergaard P. Epilepsy, osteoporosis and fracture risk-a meta-analysis. Acta NeurolScand. 2005;112(5):277-86.
23. Verrotti A, Lattanzi S, Brigo F, Zaccara G. Pharmacodynamic interactionsofantiepileptic drugs: From bench to clinical practice. Epilepsy Behav. 2020;104(Pt A):106939.
24. Birnbaum AK, Hardie NA, Conway JM, Bowers SE, Lackner TE, Graves NM, et al.Phenytoin use in elderly nursing home residents. Am J Geriatr Pharmacother. 2003;1(2):90-5.
25. Sazgar M. Kidney Disease and Epilepsy. J Stroke Cerebrovasc Dis. 2021:105651.
26. Mahmoud SH, Zhou XY, Ahmed SN. Managing the patient with epilepsy and renalimpairment. Seizure. 2020;76:143-52.
27. Hauser WA, Annegers JF, Kurland LT. Incidence of epilepsy and unprovoked seizuresin Rochester, Minnesota: 1935-1984. Epilepsia. 1993;34(3):453-68.
28. Silverman IE, Restrepo L, Mathews GC. Poststroke seizures. Arch Neurol.2002;59(2):195-201.
29. Sung CY, Chu NS. Epileptic seizures in thromboticstroke. J Neurol. 1990;237(3):166-70.
30. Graham NS, Crichton S, Koutroumanidis M, Wolfe CD, Rudd AG. Incidence andassociations of poststroke epilepsy: the prospective South London Stroke Register. Stroke.2013;44(3):605-11.
31. Lahti AM, Saloheimo P, Huhtakangas J, Salminen H, Juvela S, Bode MK, et al.Poststroke epilepsy in long-term survivors of primary intracerebral hemorrhage. Neurology.2017;88(23):2169-75.
32. Velioglu SK, Ozmenoglu M, Boz C, Alioglu Z. Status epilepticus after stroke. Stroke.2001;32(5):1169-72.
33. Gupta SR, Naheedy MH, Elias D, Rubino FA. Postinfarction seizures. A clinical study.Stroke. 1988;19(12):1477-81.
34. Wang JZ, Vyas MV, Saposnik G, Burneo JG. Incidence and management of seizuresafter ischemic stroke: Systematic reviewand meta-analysis. Neurology. 2017;89(12):1220-8.
35. Armstrong TS, Grant R, Gilbert MR, Lee JW, Norden AD. Epilepsy in glioma patients:mechanisms, management, and impact of anticonvulsant therapy. Neuro Oncol. 2016;18(6):779-89.
36. Happold C, Gorlia T,Chinot O, Gilbert MR, Nabors LB, Wick W, et al. Does ValproicAcid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective ClinicalTrials in Newly Diagnosed Glioblastoma. J Clin Oncol. 2016;34(7):731-9.
37. van Breemen MS, Wilms EB, Vecht CJ. Epilepsy in patients with brain tumours:epidemiology, mechanisms, and management. Lancet Neurol. 2007;6(5):421-30.
38. Kerrigan S, Grant R. Antiepileptic drugs for treating seizures in adults with braintumours.Cochrane Database Syst Rev. 2011(8):CD008586.
39. Kerkhof M, Koekkoek JAF, Vos MJ, van den Bent MJ, Taal W, Postma TJ, et al.Withdrawal of antiepileptic drugs in patients with low grade and anaplastic glioma after long-termseizure freedom: a prospective observational study.J Neurooncol.2019;142(3):463-70.
40. Weller M, Gorlia T, Cairncross JG, van den Bent MJ, Mason W, Belanger K, et al.Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma.Neurology.2011;77(12):1156-64.
41. van der Meer PB, Dirven L, Fiocco M, Vos MJ, Kouwenhoven MCM, van den Bent MJ,et al.First-line antiepileptic drug treatment in glioma patients with epilepsy: Levetiracetam vsvalproic acid. Epilepsia. 2021;62(5):1119-29.
42. Steriade C, Britton J, Dale RC, GadothA, Irani SR, Linnoila J, et al. Acute symptomaticseizures secondary to autoimmune encephalitis and autoimmune-associated epilepsy: Conceptualdefinitions. Epilepsia. 2020;61(7):1341-51.
43. Seo JH, Lee YJ, Lee KH, Gireesh E, Skinner H, Westerveld M. Autoimmune encephalitisand epilepsy: evolving definition and clinical spectrum. Clin Exp Pediatr. 2020;63(8):291-300.
44. Cabezudo-Garcia P, Mena-Vazquez N, Villagran-Garcia M, Serrano-Castro PJ. Efficacyof antiepileptic drugs in autoimmune epilepsy: A systematic review. Seizure. 2018;59:72-6.
45. Wesselingh R, Butzkueven H, Buzzard K, Tarlinton D, O'Brien TJ, Monif M. Seizures inautoimmune encephalitis: Kindling the fire. Epilepsia. 2020;61(6):1033-44.